1. Table 1. Characteristics of patients and the results of the log-rank test of prognostic factors Median (range) No. of patients No. of CRPC Median progression time (months) No. of deaths Median survival time (months) Total 28620719 102113 Age73 (50-91) ≤75 17913219 6985 ≥76 1077518n.s.33nonen.s. TT142570all alive T23118379111 T3162114196083 T48973143377n.s. NN0 16411619 5979 N1 1229119n.s.4399n.s. MM0503126999 M123617618n.s.9383n.s. Gleason score6-8 1818321 63115 9-10 10512414 3985 n.s. PSA at diagnosis174 (5.7-21864) <10010564233185 100-50097731636113 ≥50084701535nonen.s. Nadir PSA level0.3 (0.001-650) <0.2 1227138 26115 0.2-4 1128613 4462 ≥4≥4 52508 3225 Time from PADT to nadir9.45 (1-64) ≥12114743523113 6-128362133979 <6897174028 Time from PADT to CRPC 13 (1-97) No CRPC 79 14none ≥12 112 32113 6-12 63 3435 <6 32 2221 * P<0.05, ** P<0.005, *** all P<0.001, **** P<0.001 without CRPC v.s. ≥12 PADT: primary androgen deprivation therapy CRPC: castration resistant prostate cancer ** *** **** **

2. TABLE 2. Hazards Ratio Estimates and Confidence Intervals from Proportional Hazards Modeling of Progression to CRPC Univariate analysisMultivariate analysis Hazard Ratio95% C.I.P value Hazard Ratio95% C.I.P value Age 0.9930.975-1.0110.425 0.990.972-1.0070.248 TT11 T21.3590.315-5.8670.681 T32.1420.528-8.6910.286 T43.3360.816-13.6470.094 Gleason score6-81 1 9-101.5181.148-2.0090.003 1.3621.023-1.8130.034 PSA at diagnosis<10011 100-5001.3740.981-1.9230.0640.990.691-1.4170.955 ≥5001.6161.149-2.2710.0061.0090.682-1.4920.965 Nadir PSA level<0.21 1 0.2-42.7782.011-3.836<0.001 2.7941.984-3.936<0.001 ≥4≥46.3394.315-9.313<0.001 6.3324.066-9.861<0.001 Time from PADT to nadir≥1211 6-122.0911.480-2.953<0.0012.2451.559-3.232<0.001 <64.1312.956-5.774<0.001 4.4083.099-6.271<0.001 95% C.I.: 95% confidence interval PADT: primary androgen deprivation therapy CRPC: castration resistant prostate cancer

3. TABLE 3. Hazards Ratio Estimates and Confidence Intervals from Proportional Hazards Modeling of Overall Survival Univariate analysis Multivariate analysis Hazard Ratio95% C.I.P value Hazard Ratio95% C.I.P value Age0.9870.962-1.0130.324 0.9940.967-1.0210.647 Nadir PSA level<0.211 0.2-43.0381.852-4.982<0.0012.3291.342-4.0400.003 ≥4≥474.109-11.925<0.0015.2212.757-9.889<0.001 Time from PADT to nadir≥121 1 6-122.5441.473-4.3930.001 1.4830.789-2.7890.221 <66.9184.174-11.467<0.001 4.0082.137-7.517<0.001 Time from PADT to CRPCNo CRPC11 ≥120.9630.509-1.8220.9070.7180.367-1.4070.335 6-124.3232.310-8.089<0.0011.4190.664-3.0310.367 <69.0214.570-17.808<0.001 1.7120.731-4.0050.215 95% C.I.: 95% confidence interval PADT: primary androgen deprivation therapy CRPC: castration resistant prostate cancer